ArchiMed to take Esperion Therapeutics private for $1.1bn
Friday, May 1, 2026 · first reported by PE Hub
ArchiMed to acquire Esperion Therapeutics for $1.1bn in take-private transaction, expected to close Q3 2026.
- Firm
- ArchiMed
- Also named
- Esperion Therapeutics
- Deal value
- $1.1B
- Asset class
- Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- Antin agrees sale of majority stake in Vicinity Energy to Harrison StreetPrivate Equity Wire +3
- CPP Investments sells A$4.5bn Australian toll road stakes to TransurbanIPE Real Assets
- Sycamore nears $9bn sale of Boots to Weston familyPrivate Equity Wire
- Eagle Point backs $450m US government-leased real estate recapitalisationIPE Real Assets
- CSC acquires 50% Watergardens mall stake from QIC for A$480mIPE Real Assets
- Lone Star buys €216m Dutch residential portfolio from Catella fundIPE Real Assets